2018 FDA Leads Side effects 
World of DTC Marketing
FEBRUARY 22, 2021
billion in 2018, and is expected to grow at a CAGR of 7.20% to reach $86.01 This has abuse potential written all over it and could lead to more dangerous health problems. Did I mention that they are using a flying pig in their DTC? billion by 2026. First, the problem of sleep apnea. Americans average 6.8
pharmaphorum
SEPTEMBER 16, 2022
Minor side effects to long-term maintenance balance. Any clinical study seeks to achieve maximum results efficacy with minimal occurrence of side effects. However, side effects do happen. Regarding both common cold and headache, they are as well among the side effects reported for similar drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 23, 2024
Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). Imran joined Oncology US Medical Affairs in 2018 as the Therapeutic Area Lead, Lymphoma and Myeloid Malignances.
European Pharmaceutical Review
OCTOBER 19, 2023
The development of novel radiotherapeutics ushered in a new era in targeted treatment 1 for cancer, with two separate radiotherapeutic approvals in Europe and the US, in 2018 and 2022. Can you share an update on the clinical trial for your lead candidate? Recent advancements for radiopharmaceuticals in oncology include a $1.4
Pharmaceutical Technology
JANUARY 22, 2023
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases. The company plans to submit an MAA to the EMA in H1 this year.
Pharmaceutical Technology
NOVEMBER 30, 2022
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Novo Nordisk is another company leading the charge in this field. The same can be said for the US.
Pharmaceutical Technology
NOVEMBER 30, 2022
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Novo Nordisk is another company leading the charge in this field. The same can be said for the US.
Expert insights. Personalized for you.
181 
Let's personalize your content